PO.CL07.05 · 临床研究
MGT-1143, a novel CDH17-targeting ADC for gastrointestinal cancers
作者与单位
摘要 Abstract
Background: Pan-gastrointestinal cancers represent a heterogeneous group of malignancies arising from the gastrointestinal tract, including esophageal, gastric, pancreatic, and colorectal cancers, which collectively contribute to a major global cancer burden and mortality. Cadherin-17 (CDH17), a Ca²⁺-dependent adhesion molecule, is overexpressed across multiple GI cancers and has been associated with poor prognosis. Here, we report the development and preclinical evaluation of MGT-1143, a novel Exatecan-based ADC that integrates a fully humanized anti-CDH17 monoclonal antibody (mAb) with Marigold's proprietary linker platform. MGT-1143 is currently undergoing IND-enabling studies.
Methods: The preclinical activity of MGT-1143 was assessed through a series of in vitro and in vivo studies to characterize its pharmacological and safety profiles. Binding affinity, cross-species reactivity, and target specificity of MGT-1143 were evaluated using ELISA and flow cytometry. Antibody internalization was determined by flow cytometry, while cytotoxicity was assessed using the CellTiter-Glo luminescent viability assay. In vivo anti-tumor efficacy was evaluated in CDH17-positive cell line-derived xenograft (CDX) models.
Results: The MGT-1143 antibody exhibited high target specificity with no detectable cross-reactivity toward other cadherin family members. MGT-1143 demonstrated strong binding affinity and rapid internalization in CDH17-expressing cells, resulting in potent cytotoxicity across multiple CDH17-positive cell lines. Furthermore, MGT-1143 induced robust and dose-dependent anti-tumor activity in xenograft mouse models expressing varying levels of CDH17, confirming its target-dependent efficacy.
Conclusions: Collectively, the preclinical data support the continued development of MGT-1143 as a promising therapeutic candidate for the treatment of CDH17-positive gastrointestinal cancers. Ongoing IND-enabling studies will further define its safety and translational potential.
利益披露 Disclosure
M. He,
Marigold Therapeutics, Inc. Employment.
P. Chao,
Marigold Therapeutics, Inc. Employment.
S. Tsai,
Marigold Therapeutics, Inc. Employment.
J. Li,
Marigold Therapeutics, Inc. Employment.
T. Hung,
Marigold Therapeutics, Inc. Employment.
M. Tsai,
Marigold Therapeutics, Inc. Employment.
C. Tsai,
Marigold Therapeutics, Inc. Employment.